松龄血脉康胶囊联合血管紧张素Ⅱ受体拮抗剂治疗高血压的系统评价简

目的 系统评价松龄血脉康胶囊联合血管紧张素Ⅱ受体拮抗剂（ARB）治疗高血压的疗效及安全性.方法 计算机检索Cochrane图书馆（2012年第4期）、EMBase、PubMed、中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、中文科技期刊全文数据库（VIP）关于松龄血脉康胶囊联合ARB治疗高血压的随机对照试验,检索时间均从创建至2013年3月,用RevMan 5.16软件对数据进行Meta分析.结果 共纳入8篇RCT,包括1 239例患者.与ARB治疗组相比,联合治疗组有效率较高OR=2.69,95％ CI（1.79,4.04）,P＜0.000 01],收缩压（SBP）降低幅度较高MD=8.50,95％ CI（6.91,-10.09）,P＜0.000 01],舒张压（DBP）降低幅度较高MD=10.56,95％ CI（6.16,14.95）,P＜0.000 01],总胆固醇（TC）降低幅度较高MD=0.64,95％ CI（0.45,0.84）,P＜0.000 01],三酰甘油（TG）降低幅度较高MD =0.30,95％ CI（0.08,0.52）,P=0.009],高密度脂蛋白胆固醇（HDL-C）升高幅度较高MD =0.20,95％ CI（0.13,0.26）,P＜0.00001].两组均未发现严重不良反应.结论 基于现有临床证据,松龄血脉康胶囊联合ARB对高血压有效且安全性好.但由于纳入研究质量不统一,此结论尚需要更多大样本、高质量临床随机对照试验予以证实.

A Systematic Review on Songlingxuemaikang Capsule Combined ARB for Treating Hypertension

Objective To evaluate the effects and safety of Songlingxuemaikang Capsule combined angiotension receptor blocker（ARB） for treating hypertension.Methods The randomized controlled trials（RCTs） of Songlingxuemaikang Capsule combined ARB for treating hypertension in the Cochrane Library （Issue 4,2012）,EMbase,PubMed,CBM,CNKI and VIP（from their establishment to March 2013） were retrieved by computer.The data were performed the meta analysis by the RevMan 5.16 software.Results 8 RCTs involving 1 239 patients were ultimately included.The results of meta-analysis showed that compared with the ARB treatment group,the effective rate of the Songlingxuemaikang Capsule combined ARB group was higher than that of the ARB group OR=2.69,95% CI（1.79,4.04）,P 〈 0.000 01] ;the reduction range of systolic blood pressure（SBP） in the Songlingxuemaikang Capsule combined ARB group was higher than that in the ARB group,MD =8.50,95% CI（6.91,-10.09）,P 〈 0.000 01] ; the reduction range of diastolic blood pressure（DBP） in the Songlingxuemaikang Capsule combined ARB group wa higher than that in the ARB group,MD=10.56,95% CI （6.16,14.95）,P 〈 0.000 01];the reduction range of TC in the Songlingxuemaikang Capsule combined ARB group was higher than that in the ARB group,MD=0.64,95% CI（0.45,0.84）,P 〈 0.000 01];the reduction range of TG in the Songlingxuemaikang Capsule combined ARB group was？higher than that in the ARB group,MD=0.30,95% CI（0.08,0.52）,P=0.009],the increased range of HDL-C in the Songlingxuemaikang Capsule combined ARB group was higher than that in the ARB groupMD =0.20,95% CI （0.13,0.26）,P 〈 0.000 01];above differences in the researches between the two groups had statistical significance.No serious adverse reactions were found in the two groups.Conclusion Based on the present clinical evidences,Songlingxuemaikang Capsule combined ARB is effective and has good safety for treating hypertension.However,due to the disunity quality of the included studies,this conclusion needs more large sample and high-quality RCTs to verify.